Comparative Pharmacology
Head-to-head clinical analysis: INCIVEK versus RIMANTADINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INCIVEK versus RIMANTADINE HYDROCHLORIDE.
INCIVEK vs RIMANTADINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibitor of the HCV NS3/4A serine protease, preventing cleavage of the HCV polyprotein, thereby inhibiting viral replication.
Rimantadine is a tricyclic amine antiviral that inhibits influenza A virus replication by blocking the M2 proton ion channel, preventing viral uncoating and release of viral RNA into host cells.
Incivek (telaprevir) is administered orally at a dose of 750 mg (two 375 mg tablets) three times daily (every 7-9 hours) with food (not low-fat).
100 mg orally twice daily for 7 days; initiate within 48 hours of symptom onset.
None Documented
None Documented
Terminal elimination half-life ranges from 4 to 13 hours (mean ~7 hours) in healthy volunteers; prolonged to 10-20 hours in HCV-infected patients.
25.4 hours (range 13–65 h); prolonged in elderly (38 h) and severe renal impairment (CrCl <10 mL/min: up to 130 h).
Approximately 91% of the radiolabeled dose is recovered in feces (79% as unchanged drug) and 9% in urine (1% as unchanged drug).
Renal: 75% unchanged; fecal: <10%; biliary: minimal. Total clearance 2.5 mL/min/kg.
Category C
Category A/B
Antiviral
Antiviral